USA flag logo/image

An Official Website of the United States Government

Complement Inhibitors for Macular Degeneration

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
93767
Program Year/Program:
2009 / SBIR
Agency Tracking Number:
EY019191
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
NOVELMED THERAPEUTICS, INC.
11000 Cedar Avenue, 135 CLEVELAND, OH 44106-0000
View profile »
Woman-Owned: Yes
Minority-Owned: Yes
HUBZone-Owned: Yes
 
Phase 1
Fiscal Year: 2009
Title: Complement Inhibitors for Macular Degeneration
Agency: HHS
Contract: 1R43EY019191-01A1
Award Amount: $212,118.00
 

Abstract:

DESCRIPTION (provided by applicant): Age-related macular degeneration (AMD) affects nearly 10 million people in the U.S (Research to Prevent Blindness Foundation). Recently approved anti-VEGF therapy is the only cure for wet AMD as of today. Recent studies have demonstrated the role of the alternative pathway (AP) in AMD. Gradual loss of vision eventually resulting in blindness is the key symptom of AMD in the adult population. Using the mouse AMD model, Bora et al demonstrated that complement factor B of t he alternative pathway plays an important role in the disease. With the use of siRNA techniques, Dr. Bora demonstrated that silencing of the factor B gene prevents the induction and persistence of AMD. Encouraged by these results, we decided to evaluate th e effect of our blocking anti-factor B monoclonal antibody (Bikaciomab) in inhibiting the development and progression of AMD. Bikaciomab binds factor B protein in human blood and blocks its function in AP mediated complement activation. Bikaciomab prevents alternative pathway mediated formation of C3a, C5a, and C5b-9, the key anaphylatoxins responsible for the inflammatory responses. We will test the effect of this blocking anti-factor B antibody in prophylaxis and established models of the disease to provi de direct clinical relevance of the drug under testing. PUBLIC HEALTH RELEVANCE: Age-related macular degeneration (AMD) affects nearly 10 million people in the U.S (Research to Prevent Blindness Foundation). Recently approved anti-VEGF therapy is the only cure for wet AMD as of today. There is an unmet medical need in the area of macular degeneration. NovelMed's current approach focuses on neutralizing factor B function and providing disease benefit. Using the previously developed animal models of AMD, Nove lMed intends to test its lead complement inhibitor for the treatment of AMD. Potent activity of Bikaciomab in vitro, ex vivo and in vivo makes the drug as a potential therapeutic for not only AMD but also for several diseases where alternative pathway play s an important role in disease pathology.

Principal Investigator:

Rekha Bansal
4404779874
REKHA@NOVELMED.COM

Business Contact:

Rekha Bansal
rekha@novelmed.com
Small Business Information at Submission:

NOVELMED THERAPEUTICS, INC.
NOVELMED THERAPEUTICS, INC. 2265 ENTERPRISE PKWY TWINSBURG, OH 44087

EIN/Tax ID: 421597802
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No